This webinar details the history of federal regulation of laboratory-developed tests including requirements under CLIA and FDA’s interpretation of its authority under the Food Drug & Cosmetic Act (FDCA). Key policy pronouncements by the FDA for overseeing LDTs will be detailed including: the agency’s stance on a subset of LDTs known as In Vitro Diagnostic Multivariate Index Assays (IVDMIAs); FDA’s plan for a comprehensive framework for LDT oversight; its release of draft documents describing the agency’s proposed regulatory framework for LDTs and subsequent withdrawal and FDA’s “discussion paper” which outlines a substantially revised “possible approach” to the oversight of LDTs.
Course Objectives:
The increasing complexity, availability and growing use of LDTs to diagnose common but serious medical conditions such as cancer and heart disease, has sparked FDA’s renewed scrutiny and related policy positions on LDTs which have drawn the attention of Congress and raised serious concerns inside the lab industry. With advances in technology and growing demand for personalized treatment plans, increasing numbers of laboratories are developing and using custom diagnostic tests to keep pace with the changing face of disease as well as to best serve both patients and clinicians alike. Though LDTs have long been subject to the regulatory requirements under the Clinical Laboratory Improvement Amendments (CLIA) FDA’s growing involvement with LDTs leaves affected labs with trying to understand how they would be affected by the prospect for additional federal oversight. Meantime, an April discussion draft for new congressional legislation, the Diagnostics Accuracy and Innovation Act (DAIA) which would affect the regulatory framework of both LDTs and in Vitro diagnostic (IVD) test kits adds yet another piece to the complex federal jigsaw puzzle for regulating LDTs.
Course Outline:
The webinar will cover the federal regulatory approach to regulating laboratory-developed tests including the role of CLIA, the rationale for and opposition to direct FDA oversight, the goal of possible federal legislation and the prospects for future action by the FDA and/or Congress. Among key elements of LDT regulation to be discussed include:
• Regulatory requirements under CLIA
• FDA’s interpretation of its authority to regulate lab tests under the Food Drug & Cosmetic Act
• FDA’s reasoning for applying enforcement discretion to LDTs
• The agency’s plan and subsequently proposed guidance to regulate a newly defined subset of LDTs, In Vitro Diagnostic Multivariate Index Assays (IVDMIAs)
• FDA’s position for issuing warning letters to labs regarding
• FDA approach under its proposed regulatory framework for LDTs
• Industry’s reasoning for opposing FDA oversight of LDTs
•
• FDA latest thinking on “possible approach” to regulating LDTs
• How possible new federal legislation would impact LDT oversight
•
What You Get:
• Training Materials
• Live Q&A Session with our Expert
• Participation Certificate
• Access to Signup Community (Optional)
• Reward Points
Who Will Benefit:
• Clinical Pathologists
• Senior Laboratory Executives in academic, research, hospital and independent labs including CEOs, COOs, CFOs
• Medical Directors
• Administrative Directors & Senior Managers
• Directors of Reimbursement, Billing & Finance
• Head of Legal and Compliance Office
Analyzing Assay Validation for Clinical Diagnostics
Get Instant Access 60 Minutes View Program |
Protocol Deviations: Documenting, Managing, and Reporting
Get Instant Access 60 Minutes View Program |
Adverse Event Reporting Understanding Regulatory Reporting Requirements
Get Instant Access 60 Minutes View Program |
The Sunshine Act: Reporting for Clinical Trials
Get Instant Access 60 Minutes View Program |
The Secret of Study Conduct Documentation to ensure a successful Audit: What the FDA Inspectors looks for
Get Instant Access 90 Minutes View Program |
Get Instant Access On-Demand Access
Preparing for the ICE Storm: What to Do During I 9 Audits and ICE Raids
Janette S. Levey
Human Resources
Get Instant Access On-Demand Access
OSHA Inspections and Investigations-How to Manage Them
Irwin Dobrushin
Environment Health and Safety | OSHA
Get Instant Access On-Demand Access
29 CFR 1904: OSHA's New Injury Recordkeeping E-Submission Rule
Occupational Safety and Health Administration
Get Instant Access On-Demand Access
Working with Excel Databases: Sort, Filter, Subtotal and More
Cathy Horwitz
Cross Industry | Skill Enhancement
Get Instant Access On-Demand Access
Writing Audit Reports
Jonnie T. Keith CIA, CFE, CGAP, CICA
Governance, Risk and Compliance
Get Instant Access On-Demand Access
BSA Reporting Requirements
Banking and Financial Services Industry
Get Instant Access On-Demand Access
Human Factors-Usability Based on ISO 62366
Medical Device | Diagnostic | Pharmaceutical | Biologics fields
Get Instant Access On-Demand Access
Chat GPT for Project Managers
Charles H. Paul
All FDA Regulated Industry